

Since 2007, the CDC has published the National Immunization Survey for teen populations. This survey is similar to the childhood NIS. Survey responses are collected via telephone through random digit dialing. Those who participate are asked to provide health care provider information so their verbal responses over the phone can be validated through the official immunization record. Children ages 13-17 were included in the study. Participants were asked about receiving meningococcal conjugate vaccine (MCV4), MMR, Hepatitis B, Varicella, Td or Tdap, and HPV (beginning in 2007). In 2006, nearly 5,500 people responded over the phone and provider-reported vaccination records were provided for 2,882 adolescents. In 2007, nearly 5,500 people responded over the phone and provider-reported vaccination records were provided for 2,947 adolescents. The CDC identifies 4 limitations in this survey: there could be bias due to non-response and households without landline telephones; it assumes that coverage levels for adolescents are similar among adolescents whose providers could verify immunizations and providers who could not; vaccines administered in non-traditional settings such as emergency rooms may not be included, and; the provider verified response rates were low (53%). Results from this survey have been reported only on a national level. State results will be available in the future. National levels can be seen in the tables below. A percentage in red indicates significant improvement over the previous year.

NIS Teen 2006, Ages 13-17 ⁱ		
Vaccine/Vaccine Series	Coverage	95% Confidence Interval
MCV4, 1 dose	11.7%	10.3%-13.2%
MMR, ≥2 doses	86.9%	85.2%-88.5%
Hepatitis, ≥3 doses	81.3%	79.4%-83.1%
Varicella, ≥1 dose among adolescents without history of varicella disease	65.5%	61.4%-69.4%
Td, ≥1 dose	49.4%	47.0%-51.7%
Tdap, ≥1 dose	10.8%	9.4%-12.3%

NIS Teen 2007, Ages 13-17 ⁱⁱ		
Vaccine/Vaccine Series	Coverage	95% Confidence Interval
MCV4, 1 dose	32.4%	30.2%-34.7%
MMR, ≥2 doses	88.9%	87.3%-90.4%
Hepatitis, ≥3 doses	87.6%	86.0%-89.0%
Varicella, ≥1 dose among adolescents without history of varicella disease	75.7%	72.2%-79.0%
Td, ≥1 dose	41.9%	39.6%-44.3%
Tdap, ≥1 dose	30.4%	28.2%-32.7%
HPV4, ≥1 dose	25.1%	22.3%-28.1%